Product
Help
Pricing
About
Jobs
Log in
Get started
Work
Add to collection
Fabry disease: overall effects of agalsidase alfa treatment
HTML
Details
Locations
Year:
2004
Type:
article
Source:
European Journal of Clinical Investigation
DOI:
10.1111/j.1365-2362.2004.01424.x
Authors:
M. Beck,
R. Ricci,
U. Widmer,
F. Dehout,
A. García De Lorenzo,
C. Kampmann,
A. Linhart,
G. Sunder‐Plassmann,
G. Houge,
U. Ramaswami,
A. Gal,
A. Mehta
show all 12
Institutions:
Johannes Gutenberg University Mainz,
University of Zurich,
HUmani - CHU Charleroi-Chimay,
Charles University,
Medical University of Vienna,
Haukeland University Hospital,
Addenbrooke's Hospital,
Universität Hamburg,
The Royal Free Hospital
show all 9
Language:
English
Topic:
Lysosomal Storage Disorders Research
Subfield:
Genetics (clinical)
Field:
Medicine
Domain:
Health Sciences
Keywords:
Fabry disease,
agalsidase alfa,
enzyme replacement therapy,
alpha-galactosidase A,
globotriaosylceramide,
renal function,
glomerular filtration rate,
left ventricular dimensions,
cardiac hypertrophy,
pain,
quality of life,
natural history (disease),
Fabry Outcome Survey
show all 13
SDG:
Good health and well-being
Open Access status:
closed
OpenAlex ID:
W2154062927
FWCI:
13.31
Cites:
24
Cited by:
239
Related to:
10